Business Development Associate Director, Oncology

We are looking for a driven and highly motivated Business Development Associate Director, Oncology, to join our growing Oncology Business Development & Licensing team. This role is designed for an ambitious BD professional with deal-making experience in the field of development therapeutics, who is ready to take the next step in their career. Reporting to a senior BD&L leader, the successful candidate will support oncology BD&L activities, contribute to deal-making processes, and help advance business opportunities across new and existing portfolio assets. This is a hands-on role for a curious, commercially minded, business-engaged talent who is eager to grow within a global oncology organization. Key Responsibilities Support deal-making processes for preclinical and clinical-stage oncology assets.Support business activities related to lifecycle management of the existing oncology portfolio.Coordinate cross-functional activities to enable efficient and well-aligned deal processes.Build and maintain effective relationships with internal stakeholders and external partners.Work closely with senior BD&L leadership to support project planning, execution, and follow-through.Prepare clear, high-quality materials to support internal governance and senior leadership decision-making.Support oncology BD&L activities focused on identifying and advancing new business opportunities.Ensure business activities are conducted in line with company standards, governance processes, and compliance requirements. Required Experience and Qualifications Degree in life sciences or equivalent; a degree in law or economics may also be relevant.MBA from a leading business school is a strong advantage.3+ years of experience in business development in the pharma/biotech industry, preferably in oncology, with hands-on experience supporting collaborations and in-/out-licensing agreements.Knowledgeable in deal-making trends and the oncology landscape. Skills and Capabilities Ability to understand oncology science and translate it into business relevance.Business acumen, with the ability to contribute significantly to key business case assumptions.Ability to manage requests from senior internal stakeholders and lead contracting alignment across cross-functional teams.Strong analytical skills, capable of generating meaningful business insights and precise deal benchmarking.Agile team player able to manage multiple parallel projects from planning through execution, with increasing autonomy and ownership over time.Strong team orientation with excellent communication and presentation skills.Flexible, versatile, collaborative, and comfortable working across multiple functions and geographies.Willingness to travel internationally as needed, approximately 15%.

The Menarini Group: Innovation, Ethics, and Global Impact Founded in 1886 and headquartered in Florence, Italy, the Menarini Group is a leading international pharmaceutical company dedicated to providing high-quality therapeutics and advanced diagnostics for patients globally.Our foundation is built upon four key pillars: People Care, Patient Focus, Quality, Responsibility & Integrity Key Facts Global Reach: Present in 70 countries, with products sold in 140 locations worldwide.Team: Around 18,000 employees globally.Manufacturing: 18 manufacturing sites across 6 continents, producing over 500 million packs of drugs annually. Our Focus on Oncology Menarini has made a strong, strategic commitment to Oncology, combining innovative therapeutic solutions with advanced liquid biopsy-based diagnostics to drive faster, more effective, and precise patient management.Our oncology portfolio has been significantly strengthened through the acquisition of Stemline Therapeutics and key licensing agreements, marking our entry into the U.S. oncology market and expanding our presence in Europe and beyond.Key examples of our cutting-edge work include:Targeted Therapies: Developing first-in-class targeted therapies for rare hematological cancers, including a treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN), and licensed oral agents for hematologic cancers and solid tumors, such as a first-in-class Selective Inhibitor of Nuclear export compound (for which we hold commercialization rights in Europe).Endocrine Therapies: Advancing late-stage oral therapies, like a Selective Estrogen Receptor Degrader (SERD), for the treatment of hormone receptor-positive advanced breast cancer.Advanced Diagnostics: Our affiliate, Menarini Silicon Biosystems (MSB), is a pioneer in rare cell analysis and non-invasive diagnostics. Their Circulating Tumour Cell (CTC) Test is the only FDA-cleared blood test for detecting and counting CTCs in certain metastatic cancers.This is an exciting time of growth and development for the company. We invite talented individuals to join us in shaping and building the future of the Menarini Stemline Oncology business.